RESUMO
Sardinella zunasi Bleeker, an edible and medicinal marine fish, is largely distributed in tropical oceans. However, the chemical composition and nutritional properties of this species have not yet been investigated. In the present study, proximate composition, fatty acids, amino acids, taurine, and minerals of S. zunasi Bleeker were characterized, and the immunostimulatory properties of its glycoprotein were evaluated. The results indicated the presence of crude protein (19.66%), crude lipid (6.29%) and carbohydrate (0.74%) in S. zunasi Bleeker; monounsaturated fatty acids and polyunsaturated fatty acids in the fatty acid composition of S. zunasi Bleeker were 25.00% and 31.01%, respectively; S. zunasi Bleeker was rich in taurine (219 mg/100 g) and essential amino acids (5.57 g/100 g). In addition, the glycoprotein of S. zunasi consisted of protein and sugars, with a total content of 34.25% and 16.27%, respectively. The glycoprotein showed significant effects on promoting NO, TNF-α and IL-6 in a dose-dependent manner in RAW264.7 macrophage cells. Thus, these findings provide a scientific basis for the further utilization of glycoprotein from S. zunasi Bleeker.
RESUMO
Imidacloprid is a key insecticide extensively used for control of Nilaparvata lugens, and its resistance had been reported both in the laboratory selected strains and field populations. A target site mutation Y151S in two nicotinic acetylcholine receptor subunits and enhanced oxidative detoxification have been identified in the laboratory resistant strain, contributing importantly to imidacloprid resistance in N. lugens. To date, however, imidacloprid resistance in field population is primarily attributable to enhanced oxidative detoxification by over-expressed P450 monooxygenases. A resistant strain (Res), originally collected from a field population and continuously selected in laboratory with imidacloprid for more than 40 generations, had 180.8-fold resistance to imidacloprid, compared to a susceptible strain (Sus). Expression of different putative P450 genes at mRNA levels was detected and compared between Res and Sus strains, and six genes were found expressed significantly higher in Res strain than in Sus strain. CYP6AY1 was found to be the most different expressed P450 gene and its mRNA level in Res strain was 17.9 times of that in Sus strain. By expressing in E. coli cells, CYP6AY1 was found to metabolize imidacloprid efficiently with initial velocity calculated of 0.851 ± 0.073 pmol/min/pmol P450. When CYP6AY1 mRNA levels in Res strain was reduced by RNA interference, imidacloprid susceptibility was recovered. In four field populations with different resistance levels, high levels of CYP6AY1 transcript were also found. In vitro and in vivo studies provided evidences that the over-expression of CYP6AY1 was one of the key factors contributing to imidacloprid resistance in the laboratory selected strain Res, which might also be the important mechanism for imidacloprid resistance in field populations, when the target site mutation was not prevalent at present.
